Status:
RECRUITING
Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Collaborating Sponsors:
The Belux Society for Pediatric Endocrinology and Diabetology (BELSPEED)
Conditions:
Growth Hormone Deficiency
Eligibility:
All Genders
1-18 years
Phase:
NA
Brief Summary
Daily subcutaneous injections of rhGH can be burdensome for patients, leading to poor adherence and reduced growth outcomes. This has spurred the development of long-acting GH (LAGH) analogues that al...
Eligibility Criteria
Inclusion
- Belgian and Luxembourgish patients currently under rhGh treatment in its various official indications (as per the Belgian RIZIV/INAMI monitor : growth hormone deficiency, Turner Syndrome, chronic renal insufficiency, Prader-Willi syndrome, Small for gestational age, Noonan Syndrome, SHOX gene deficiency) and included in the BELGROW Registry
- Male -female
- 0-18 years
- Free written or e-consent and oral consent
Exclusion
- No exclusion criteria
Key Trial Info
Start Date :
April 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06542809
Start Date
April 15 2024
End Date
March 1 2026
Last Update
August 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cliniques Universitaires Saint-Luc
Brussels, Woluwe-saint-lambert, Belgium, 1200